By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • Technology
  • Travel
Reading: Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Share
Font ResizerAa
AdkhabarAdkhabar
  • Entertainment
  • Technology
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • Technology
  • Travel
Have an existing account? Sign In
Follow US
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Health

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNews Wire
Last updated: 27/01/2025 3:38 AM
GlobeNews Wire Published 27/01/2025
Share
SHARE

January 24, 2025 16:01 ET  | Source: Chimerix, Inc.

DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to six new employees of non-statutory stock options to purchase up to a total of 355,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).

The stock options have an exercise price per share equal to Chimerix’s closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.

CONTACTS:

Will O’Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com

You Might Also Like

Gravity Announces $13M in Series A Funding to Automate Reporting and Accelerate Energy Optimization

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions

RESOLVE 2024 Concludes with Impactful Sessions on Complex and Pressing Issues Shaping Global Dispute Resolution

NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED

Sadhguru Headlines Kayan Wellness Festival in Abu Dhabi, the Region’s Largest Wellness Gathering

TAGGED:5635(c)(4)chimerixgrantsinducementlistingnasdaqNasdaq:CMRXreportsruleuncategorizedunderUS16934W1062
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
TelegramFollow
Google NewsFollow
LinkedInFollow
MediumFollow

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!

- Advertisement -
Popular News
Hisense Secures Top Spot in 100-inch TV Global Shipments
Uncategorized

Hisense Secures Top Spot in 100-inch TV Global Shipments

11/12/2024
The Ecole normale suprieure, AI & Society Institute and Capgemini launch a global Observatory on AIs environmental impact
BLVD Live TV Secures Multi-Million-Dollar Sponsorship Deal with Medodo Coin to Power Docuseries Love & KPOP
Higer New V Series, Leading Bus New Trend
Wegofin – Future fintech unicorn in AI Banking, a Key Sponsor in IBA’s 20th Annual Technology Conference to Shape the Future of Indian Banking
- Advertisement -

Categories

  • Uncategorized
  • Health
  • Technology
  • Automobile
  • Travel
  • Esports
  • Entertainment
  • Life Style
  • Food
  • News

About US

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2024 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?